Hosted on MSN1mon
Cardiff stock soars on onvansertib data, $40M direct offeringCardiff Oncology (NASDAQ:CRDF) stock rallied 46% Tuesday after it reported positive data for its oncology drug onvansertib and priced a $40M registered direct offering. Cardiff (CRDF) said a Phase ...
Hosted on MSN1mon
Cardiff Oncology announces positive colorectal data and $40m stock oversubscriptionGlobalData is the parent company of Clinical Trials Arena. "Cardiff Oncology announces positive colorectal data and $40m stock oversubscription" was originally created and published by Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback